DEM BioPharma

DEM BioPharma is a private, pre-clinical stage biotech pioneering a novel approach to cancer immunotherapy by engaging macrophages. The company's core technology involves developing therapeutics designed to redirect and activate macrophages to attack solid tumors, an area with significant unmet need. While still early-stage, the planned presentation of preclinical data for its lead candidate, DEM301, at a major oncology conference in 2026 indicates progress. The company operates as a typical venture-backed biotech, seeking to advance its pipeline through preclinical and clinical development to create value for patients and investors.

Macrophage engager platform designed to develop bispecific/multifunctional molecules that bind tumor antigens and activating receptors on macrophages, reprogramming them to attack cancer cells.

DEM BioPharma operates in the emerging and competitive field of innate immune oncology. It competes with other biotechs like ALX Oncology (targeting CD47-SIRPα axis), Surface Oncology, and Trishula Therapeutics, as well as internal programs at large pharma companies. Its differentiation lies in the specific engineering approach of its macrophage engager molecules.